Beijing Zhendan Dingtai Biotechnology Co., Ltd.

Phase Ia dose escalation phase: Main objectives: (1) To evaluate the safety and tolerability of NMM tumor therapeutic DNA vaccine naked plasmid injection in patients with advanced solid tumors and relapsed/refractory lymphoma; (2) To determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD), and recommend the Phase II clinical trial dose (RP2D). Secondary objectives: To evaluate the preliminary efficacy of NMM tumor therapeutic DNA vaccine naked plasmid injection in patients with advanced solid tumors and relapsed and refractory lymphoma. Phase Ib dose expansion phase: Main objectives: To evaluate the safety and dose tolerance of NMM tumor therapeutic DNA vaccine naked plasmid injection in patients with advanced melanoma, advanced breast cancer and relapsed/refractory lymphoma, and to determine RP2D. Secondary objectives: To further evaluate the preliminary efficacy of NMM tumor therapeutic DNA vaccine naked plasmid injection in patients with advanced melanoma, advanced breast cancer and relapsed and refractory lymphoma. Exploratory purpose: To explore the changes in biomarkers compared with the baseline period before and after treatment with NMM tumor therapeutic DNA vaccine naked plasmid injection in patients with advanced melanoma, advanced breast cancer, and relapsed and refractory lymphoma.